The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Neuronal Synuclein Disease Endotypes 2024, 2025Development of Alpha-synuclein Seed Amplification Assay in Cerebrospinal Fluid as a Robust Biomarker of Synucleinopathies
Study Rationale: Progressive aggregation of alpha-synuclein and the subsequent loss of affected brain cells starts 10 to 20 years before the onset of Parkinson’s disease (PD) symptoms. Early diagnosis...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Developing a Method to Exclude Individuals with Insignificant Alpha-synuclein Aggregates from Trials of Therapies that Target Alpha-synuclein
Study Rationale: Alpha-synuclein is a protein that forms clumps in the brain in Parkinson’s disease (PD). Although alpha-synuclein aggregation is a common cause of dementia, other proteins are also...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Identifying Biomarkers for the Common Mechanism Underlying the Disease Continuum from Parkinson’s Disease to Alzheimer’s Disease
Study Rationale: Disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) share many similarities in their pathology. In particular, both involve accumulation of amyloid-β and alpha...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025GBA1 Consortium: Joint Analysis to Inform Clinical Trials
Study Rationale: Variants in the GB1A gene represent the most important genetic risk factor for Parkinson’s disease (PD) across the globe. However, different GBA1 variants are associated with varied...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Investigation of a Novel Therapeutic Approach for Non-motor Symptoms of Parkinson’s Disease
Study Rationale:
Parkinson's disease (PD) is characterized by both motor symptoms and non-motor symptoms. While progress has been made in addressing motor symptoms, non-motor...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Investigating the Early Events in Parkinson’s Disease Pathobiology through Longitudinal Evaluation of Asymptomatic Carriers of Alpha-synuclein Mutations
Study Rationale: Essentially nothing is known about the sequence of biological and physiological events that ultimately lead to the clinical manifestations of Parkinson’s disease (PD). The existence...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.